FDA Issues Product-Specific Guidance Documents for Chloroquine Phosphate and Hydroxychloroquine Sulfate

April 15, 2020

On Tuesday, April 14th, FDA released two product-specific guidance documents for chloroquine phosphate tablets and hydroxychloroquine sulfate tablets, two drugs being investigated as potential treatments for COVID-19.  These guidances provide product-specific recommendations on, among other things, the design of bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs).

The guidance, entitled Guidance on Hydroxychloroquine Sulfate was developed using the process described in that guidance and finalizes the draft guidance of the same title issued in April 2011. The guidance entitled Guidance on Chloroquine Phosphate is being implemented without prior public comment because FDA has determined that prior participation for this guidance is not feasible or appropriate in light of the coronavirus disease 2019 (COVID-19) public health emergency.

The guidance on Chloroquine Phosphate does not require an in-vivo demonstration of bioequivalence and only requires that the in-vitro dissolution profiles of the proposed products are comparable to those of the reference products.  The reference standard products are the chloroquine phosphate tablets manufactured by Natco Pharma Limited approved under ANDA 091621.

The guidance on Hydroxychloroquine Sulfate provides two options for demonstrating bioequivalence. Option one is to use the Biopharmaceutics Classification System (BCS)-based biowaiver; and option two is the more common in-vivo fed and fasting bioequivalence studies but measuring the hydroxychloroquine analyte in whole blood.  The reference standard product is Plaquenil® tablet manufactured by CONCORDIA PHARMACEUTICALS INC approved under NDA 009768.

Are you in the process of developing a branded or generic drug?  Regardless of the type of FDA-regulated product, we can help you achieve successful interactions with the FDA.  To learn more about our services and how we can help you, contact us today.

Agency Alerts General Regulatory

February 4, 2016

FDA Partners with Commonwealth Informatics to Build Drug Safety Analysis Platform

On January 28, 2016, the FDA and Commonwealth Informatics entered into a two-year agreement where they will work together to develop a platform to help the Agency assess drug safety data. The...

Read the Full Article
Cleaning Validation Life Science Consulting

August 17, 2016

cGMP for Phase 1 Investigational Drugs: Sterile Parenteral Drug Product Manufacturing

As Phase I clinical trials mark the first time that an investigational new drug is administered to humans, these studies are subject to appropriate current Good Manufacturing Practices (cGMP) in...

Read the Full Article
Agency Alerts

January 27, 2016

Sanders Places Hold on Obama’s Nominee for FDA Commissioner

In September 2015, President Obama nominated Robert Califf, MD, a world renowned cardiologist and clinical trial expert, to serve as the next FDA Commissioner. Following his nomination, Dr. Califf...

Read the Full Article